AbbVie Q2 Adjusted EPS $2.91 Beats $2.80 Estimate, Sales $13.87B Beat $13.52B Estimate
Portfolio Pulse from Benzinga Newsdesk
AbbVie reported Q2 earnings of $2.91 per share, beating the analyst consensus estimate of $2.80 by 3.93%. However, this is a 13.65% decrease from the same period last year. The company also reported quarterly sales of $13.87 billion, beating the estimate of $13.52 billion by 2.55%, but this is a 4.92% decrease from last year.
July 27, 2023 | 11:39 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AbbVie's Q2 earnings and sales beat estimates but are lower than the same period last year. This mixed result could lead to uncertain market reactions.
AbbVie's Q2 results exceeded analyst estimates, which is generally a positive signal for the stock. However, the decrease compared to the same period last year might concern some investors, leading to potential volatility in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100